Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Novartis
Chubb
Medtronic
Fish and Richardson
Chinese Patent Office
Merck
Harvard Business School
McKesson
Johnson and Johnson

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206488

« Back to Dashboard

NDA 206488 describes EXONDYS 51, which is a drug marketed by Sarepta Theraps Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the EXONDYS 51 profile page.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.
Summary for 206488
Tradename:EXONDYS 51
Applicant:Sarepta Theraps Inc
Ingredient:eteplirsen
Patents:5
Pharmacology for NDA: 206488
Suppliers and Packaging for NDA: 206488
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488 NDA Sarepta Therapeutics, Inc. 60923-284 N 60923-284-10
EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488 NDA Sarepta Therapeutics, Inc. 60923-363 N 60923-363-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength100MG/2ML (50MG/ML)
Approval Date:Sep 19, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 19, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Sep 19, 2023
Regulatory Exclusivity Use:TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Patent:➤ Try a Free TrialPatent Expiration:Jun 28, 2025Product Flag?Substance Flag?Delist Request?Y
Patented Use:(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Cipla
Healthtrust
Mallinckrodt
Colorcon
McKesson
Moodys
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot